BRPI1004899A2 - composto, composição farmacêutica, método para tratar uma doença ou distúrbio relacionado a pi3k em um indivíduo necessitando do mesmo, método para tratar uma doença mediada por mtor, método para tratar ambas as doenças mediadas por pi3k e hdac - Google Patents

composto, composição farmacêutica, método para tratar uma doença ou distúrbio relacionado a pi3k em um indivíduo necessitando do mesmo, método para tratar uma doença mediada por mtor, método para tratar ambas as doenças mediadas por pi3k e hdac

Info

Publication number: BRPI1004899A2
Authority: BR; Brazil
Prior art keywords: treating; pi3k; mediated; disease; hdac
Prior art date: 2009-01-08

Application number

BRPI1004899A

Other languages

English (en)

Inventor

Changgeng Qian

Cheng-Jung Lai

Haixiao Zhai

Xiong Cai

Original Assignee

Curis Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-01-08

Filing date

2010-01-08

Publication date

2016-04-05

2010-01-08 Application filed by Curis Inc filed Critical Curis Inc

2016-04-05 Publication of BRPI1004899A2 publication Critical patent/BRPI1004899A2/pt

2020-08-18 Publication of BRPI1004899B1 publication Critical patent/BRPI1004899B1/pt

2021-05-25 Publication of BRPI1004899B8 publication Critical patent/BRPI1004899B8/pt

Links

208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 4
201000010099 disease Diseases 0.000 title 3
230000001404 mediated effect Effects 0.000 title 2
101150097381 Mtor gene Proteins 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
208000035475 disorder Diseases 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Gastroenterology & Hepatology (AREA)
Dermatology (AREA)
Reproductive Health (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

BRPI1004899A 2009-01-08 2010-01-08 composto inibidor de fosfoinositida 3-quinase, composição farmacêutica e uso de um composto BRPI1004899B8 (pt)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US14327109P	2009-01-08	2009-01-08
US61/143,271		2009-01-08
US17258009P	2009-04-24	2009-04-24
US61/172,580		2009-04-24
PCT/US2010/020495 WO2010080996A1 (en)	2009-01-08	2010-01-08	Phosphoinositide 3-kinase inhibitors with a zinc binding moiety

Publications (3)

Publication Number	Publication Date
BRPI1004899A2 true BRPI1004899A2 (pt)	2016-04-05
BRPI1004899B1 BRPI1004899B1 (pt)	2020-08-18
BRPI1004899B8 BRPI1004899B8 (pt)	2021-05-25

Family

ID=42316830

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1004899A BRPI1004899B8 (pt)	2009-01-08	2010-01-08	composto inibidor de fosfoinositida 3-quinase, composição farmacêutica e uso de um composto

Country Status (25)

Country	Link
US (11)	US8367663B2 (pt)
EP (1)	EP2385832B1 (pt)
JP (3)	JP5452617B2 (pt)
KR (2)	KR20140094590A (pt)
CN (1)	CN102341108B (pt)
AU (1)	AU2010203512C1 (pt)
BR (1)	BRPI1004899B8 (pt)
CA (1)	CA2749228C (pt)
CY (1)	CY1116797T1 (pt)
DK (1)	DK2385832T3 (pt)
EA (1)	EA024252B1 (pt)
ES (1)	ES2550032T3 (pt)
HR (1)	HRP20150947T1 (pt)
HU (1)	HUE027615T2 (pt)
IL (2)	IL213976A (pt)
ME (1)	ME02230B (pt)
MX (1)	MX2011007326A (pt)
PL (1)	PL2385832T3 (pt)
PT (1)	PT2385832E (pt)
RS (1)	RS54230B1 (pt)
SG (2)	SG172908A1 (pt)
SI (1)	SI2385832T1 (pt)
SM (1)	SMT201500226B (pt)
TW (1)	TWI558710B (pt)
WO (1)	WO2010080996A1 (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2385832E (pt) *	2009-01-08	2015-11-02	Curis Inc	Inibidores de fosfoinoritide 3-quinase com uma fração de ligação ao zinco
KR20120063515A (ko) *	2009-09-09	2012-06-15	아빌라 테라퓨틱스, 인크.	Ｐｉ３ 키나제 억제제 및 이들의 용도
CA2795952A1 (en) *	2010-04-16	2011-10-20	Curis, Inc.	Treatment of cancers having k-ras mutations
JP5695200B2 (ja) *	2010-09-10	2015-04-01	ハンジョウベンシェンファーマシューティカルシーオー．，エルティーディー．ＨａｎｇｚｈｏｕＢｅｎｓｈｅｎｇＰｈａｒｍａｃｅｕｔｉｃａｌＣｏ．，Ｌｔｄ．	複素環アミノベルバミン誘導体、その調製方法及び使用
NZ610225A (en) *	2010-11-16	2015-08-28	Acetylon Pharmaceuticals Inc	Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
PL2651417T3 (pl)	2010-12-16	2017-08-31	Calchan Limited	Pochodne pirolopirymidyny hamujące ASK1
US9708299B2 (en)	2011-01-03	2017-07-18	Genentech, Inc.	Hedgehog antagonists having zinc binding moieties
EP2667874A4 (en) *	2011-01-27	2014-07-30	Univ Princeton	MTOR KINASE HEMMER AS ANTIVIRUS AGENT
WO2012118978A1 (en) *	2011-03-03	2012-09-07	The Regents Of The University Of Colorado, A Body Corporate	Methods for treating oncovirus positive cancers
PT3111938T (pt)	2011-04-01	2019-07-10	Curis Inc	Inibidores de fosfoinoritide 3-quinase com uma fração de ligação ao zinco
US20130102595A1 (en) *	2011-04-15	2013-04-25	Curis, Inc.	Treatment of cancers having k-ras mutations
EP2524918A1 (en)	2011-05-19	2012-11-21	Centro Nacional de Investigaciones Oncológicas (CNIO)	Imidazopyrazines derivates as kinase inhibitors
IN2014CN04558A (pt) *	2011-11-23	2015-09-18	Cancer Rec Tech Ltd
US9725463B2 (en)	2013-06-21	2017-08-08	Lupin Limited	Substituted heterocyclic compounds as CRAC modulators
EP3013810A1 (en)	2013-06-24	2016-05-04	Lupin Limited	Chromane and chromene derivatives and their use as crac modulators
AU2014293013A1 (en)	2013-07-26	2016-03-17	Race Oncology Ltd.	Combinatorial methods to improve the therapeutic benefit of bisantrene
WO2015054099A1 (en)	2013-10-08	2015-04-16	Acetylon Pharmaceuticals, Inc.	Combinations of histone deacetylase inhibitors and either her2 inhibitors or pi3k inhibitors
EP3055299B1 (en)	2013-10-10	2021-01-06	Acetylon Pharmaceuticals, Inc.	Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors
EP3060217B1 (en)	2013-10-24	2022-06-08	Mayo Foundation for Medical Education and Research	Treatment of polycystic diseases with an hdac6 inhibitor
EP3076973B1 (en)	2013-12-03	2020-04-29	Acetylon Pharmaceuticals, Inc.	Combinations of histone deacetylase inhibitors and immunomodulatory drugs
CN104725301A (zh) *	2013-12-20	2015-06-24	北京蓝贝望生物医药科技股份有限公司	一种1,2-二氢吡啶-2-酮衍生物的制备方法
US9464073B2 (en)	2014-02-26	2016-10-11	Acetylon Pharmaceuticals, Inc.	Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors
CN107205988A (zh)	2014-07-07	2017-09-26	埃斯泰隆制药公司	利用组蛋白脱乙酰酶抑制剂治疗白血病
MY195016A (en)	2014-08-04	2023-01-03	Nuevolution As	Optionally Fused Heterocyclyl-Substituted Derivatives of Pyrimidine Useful for The Treatment of Inflammatory, Metabolic, Oncologic and Autoimmune Diseases
CN104292242B (zh) *	2014-09-18	2017-05-17	广州必贝特医药技术有限公司	噻吩嘧啶类化合物和制剂及其制备方法和应用
CN107438436A (zh)	2014-12-05	2017-12-05	摩德纳和雷焦艾米利亚大学	用于治疗淋巴瘤的组蛋白脱乙酰酶抑制剂和苯达莫司汀的组合
CN107074873B (zh) *	2014-12-11	2022-01-07	纳科法尔马有限公司	作为抗癌药的7-(吗啉基)-2-(N-哌嗪基)甲基噻吩并[2，3-c]吡啶衍生物
AU2016250972B2 (en) *	2015-04-21	2019-01-17	Chengdu Zenitar Biomedical Technology Co., Ltd.	Purinyl-n-hydroxyl pyrimidine formamide derivative, preparation methods and uses thereof
US10272084B2 (en)	2015-06-01	2019-04-30	Regenacy Pharmaceuticals, Llc	Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy
CN105037345B (zh) *	2015-06-09	2019-01-25	天津渤海职业技术学院	抗肿瘤化合物、其制备方法和用途
CA3004534C (en) *	2015-11-23	2023-11-07	Council Of Scientific & Industrial Research	Fused pyrimidines as isoform selective phosphoinositide-3-kinase-alpha inhibitors and process for preparation thereof
US9630968B1 (en)	2015-12-23	2017-04-25	Arqule, Inc.	Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
US11813261B2 (en)	2016-04-19	2023-11-14	Acetylon Pharmaceuticals, Inc.	HDAC inhibitors, alone or in combination with BTK inhibitors, for treating chronic lymphocytic leukemia
AU2017315343A1 (en)	2016-08-24	2019-02-28	Arqule, Inc.	Amino-pyrrolopyrimidinone compounds and methods of use thereof
KR20190077040A (ko) *	2016-11-02	2019-07-02	쿠리스 인코퍼레이션	아연 결합 모이어티를 갖는 포스포이노시티드 3-키나아제 억제제를 이용하는 조합 요법
SG10202106949XA (en) *	2016-11-18	2021-07-29	Cystic Fibrosis Found	Pyrrolopyrimidines as cftr potentiators
EP3548035A4 (en)	2016-11-30	2020-07-22	Case Western Reserve University	COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES
CN110573154A (zh)	2017-02-06	2019-12-13	卡斯西部储备大学	调节短链脱氢酶活性的组合物和方法
CN108623491B (zh) *	2017-03-24	2020-12-22	联化科技股份有限公司	一种卤代苯甲酰胺化合物的制备方法
CN107163061A (zh) *	2017-04-14	2017-09-15	江西科技师范大学	含吡唑啉结构的噻吩并嘧啶类化合物的制备及应用
EP3849554B1 (en)	2018-09-11	2025-01-29	Curis, Inc.	Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
WO2020106998A1 (en)	2018-11-21	2020-05-28	Case Western Reserve University	Compositions and methods of modulating short-chain dehydrogenase activity
SG11202108274SA (en)	2019-02-06	2021-08-30	Venthera Inc	Topical phosphoinositide 3-kinase inhibitors
TWI908740B (zh)	2019-10-09	2025-12-21	美商百歐克斯製藥公司	口服補體因子d抑制劑
BR112022012205A2 (pt)	2019-12-20	2022-09-13	Nuevolution As	Compostos ativos para receptores nucleares
AU2020405446A1 (en)	2019-12-20	2022-05-26	Nuevolution A/S	Compounds active towards nuclear receptors
AU2021224268A1 (en)	2020-02-21	2022-09-15	Case Western Reserve University	Compositions and methods for treating renal injury
JP7713954B2 (ja)	2020-03-31	2025-07-28	ヌエヴォリューション・アクティーゼルスカブ	核内受容体に対して活性な化合物
CA3174252A1 (en)	2020-03-31	2021-10-07	Nuevolution A/S	Compounds active towards nuclear receptors
WO2022152229A1 (zh) *	2021-01-15	2022-07-21	深圳微芯生物科技股份有限公司	一类吗啉衍生物及其制备方法和应用
JP7736782B2 (ja) *	2021-03-29	2025-09-09	株式会社カネカ	（２－メチルピリミジン－５－イル）ボロン酸誘導体の製造方法
CN113754680B (zh) *	2021-09-28	2022-07-22	云白药征武科技(上海)有限公司	一种α氟代酰基哌嗪衍生物及其制备和应用
CN118019744A (zh) *	2021-09-30	2024-05-10	韩美药品株式会社	PIKfyve激酶抑制剂
JP2025513455A (ja)	2022-04-22	2025-04-24	バーテックスファーマシューティカルズインコーポレイテッド	疼痛の治療のためのヘテロアリール化合物
CN117865979B (zh) *	2024-01-04	2026-07-24	广州必贝特医药股份有限公司	噻吩嘧啶类化合物的晶型及其制备方法
CN119161359B (zh) *	2024-09-18	2026-03-20	辽宁大学	一种新型含丙烯酰胺结构的4-吗啉基噻吩并[3,2-d]嘧啶类化合物及其应用

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5369108A (en)	1991-10-04	1994-11-29	Sloan-Kettering Institute For Cancer Research	Potent inducers of terminal differentiation and methods of use thereof
US5502187A (en) *	1992-04-03	1996-03-26	The Upjohn Company	Pharmaceutically active bicyclic-heterocyclic amines
US6777217B1 (en)	1996-03-26	2004-08-17	President And Fellows Of Harvard College	Histone deacetylases, and uses related thereto
AU6410699A (en) *	1998-10-13	2000-05-01	Chris Cheah	Method and system for controlled distribution of information over a network
AU5261001A (en) *	2000-04-27	2001-11-12	Imperial Cancer Research Technology Ltd	Condensed heteroaryl derivatives
US6608053B2 (en)	2000-04-27	2003-08-19	Yamanouchi Pharmaceutical Co., Ltd.	Fused heteroaryl derivatives
ES2306859T3 (es)	2002-03-13	2008-11-16	Janssen Pharmaceutica Nv	Derivados de sulfonil como nuevos inhibidores de histona deacetilasa.
JP4648628B2 (ja)	2002-03-13	2011-03-09	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	ヒストンデアセチラーゼの新規な阻害剤としてのカルボニルアミノ誘導体
WO2003076401A1 (en)	2002-03-13	2003-09-18	Janssen Pharmaceutica N.V.	Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
CA2476583C (en)	2002-03-13	2011-07-05	Kristof Van Emelen	Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase
WO2004017950A2 (en)	2002-08-22	2004-03-04	Piramed Limited	Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
CN101153042A (zh) *	2003-01-29	2008-04-02	武田药品工业株式会社	噻吩并嘧啶化合物及其用途
WO2005117909A2 (en) *	2004-04-23	2005-12-15	Exelixis, Inc.	Kinase modulators and methods of use
US7218492B2 (en) *	2004-09-17	2007-05-15	Electronic Polymers, Inc.	Devices and systems for electrostatic discharge suppression
WO2006040966A1 (ja)	2004-10-08	2006-04-20	Astellas Pharma Inc.	芳香環縮合ピリミジン誘導体
GB0423653D0 (en)	2004-10-25	2004-11-24	Piramed Ltd	Pharmaceutical compounds
NZ589276A (en)	2005-02-03	2012-06-29	Topotarget Uk Ltd	Combination therapies using hdac inhibitors and erlotinib (tarceva)
DK1885710T3 (en)	2005-05-18	2015-11-23	Janssen Pharmaceutica Nv	SUBSTITUTED AMINOPROPENYLPIPERIDINE OR MORPHOLINE DERIVATIVES AS UNKNOWN INHIBITORS OF HISTONDEACETYLASE
US7731753B2 (en) *	2005-09-01	2010-06-08	Spinal Kinetics, Inc.	Prosthetic intervertebral discs
EP1940310B1 (en) *	2005-10-24	2016-08-31	Biomet 3i, LLC	Methods for manufacturing dental implant components
JP2007151829A (ja) *	2005-12-05	2007-06-21	Bridgestone Sports Co Ltd	ゴルフクラブヘッド
EP1979326B1 (en)	2006-01-19	2012-10-03	Janssen Pharmaceutica N.V.	Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
US7888360B2 (en)	2006-01-19	2011-02-15	Janssen Pharmaceutica N.V.	Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
JP5225103B2 (ja)	2006-01-19	2013-07-03	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	ヒストン・デアセチラーゼの新規なインヒビターとしてのヘテロシクリルアルキル誘導体
KR20090021155A (ko)	2006-04-26	2009-02-27	에프. 호프만-라 로슈 아게	Ｐｉ3ｋ 억제제로서의 피리미딘 유도체
KR101533461B1 (ko)	2006-04-26	2015-07-02	에프. 호프만-라 로슈 아게	Ｐｉ３ｋ저해제로 유용한 티에노［3,2-ｄ］피리미딘 유도체
PL2041139T3 (pl) *	2006-04-26	2012-05-31	Hoffmann La Roche	Związki farmaceutyczne
AU2007243466B2 (en) *	2006-04-26	2012-01-19	F. Hoffmann-La Roche Ag	Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
EP2018366A4 (en)	2006-05-16	2010-08-04	Univ Mcgill	HYBRID MOLECULES WITH MIXED VITAMIN D RECEPTOR AGONISM AND HISTONDEACETYLASE RESISTANT PROPERTIES
AU2007296745B2 (en) *	2006-09-11	2011-12-01	Curis, Inc.	Quinazoline based EGFR inhibitors
US20080234355A1 (en) *	2006-09-11	2008-09-25	Xiong Cai	Dna methyl transferase inhibitors containing a zinc binding moiety
CA2662617C (en)	2006-09-11	2014-11-18	Changgeng Qian	Quinazoline based egfr inhibitors containing a zinc binding moiety
US20080161320A1 (en)	2006-09-11	2008-07-03	Xiong Cai	Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
US7547781B2 (en)	2006-09-11	2009-06-16	Curis, Inc.	Quinazoline based EGFR inhibitors containing a zinc binding moiety
WO2008033746A2 (en)	2006-09-11	2008-03-20	Curis, Inc.	Tyrosine kinase inhibitors containing a zinc binding moiety
AU2007296740B2 (en) *	2006-09-11	2012-09-27	Curis, Inc.	Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety
SG174772A1 (en)	2006-09-11	2011-10-28	Curis Inc	Multi-functional small molecules as anti-proliferative agents
CA2667826C (en)	2006-10-28	2013-10-08	Methylgene Inc.	Inhibitors of histone deacetylase
PE20081679A1 (es)	2006-12-07	2008-12-18	Hoffmann La Roche	Compuestos del inhibidor de fosfoinositida 3-cinasa y metodos de uso
CA2671845C (en) *	2006-12-07	2015-03-24	Genentech, Inc.	Phosphoinositide 3-kinase inhibitor compounds and methods of use
CA2677651A1 (en)	2007-02-15	2008-08-21	Novartis Ag	Combinations of therapeutic agents for treating cancer
US20080234332A1 (en)	2007-03-20	2008-09-25	Xiong Cai	Raf kinase inhibitors containing a zinc binding moiety
TW200922590A (en)	2007-09-10	2009-06-01	Curis Inc	VEGFR inhibitors containing a zinc binding moiety
TW200922564A (en)	2007-09-10	2009-06-01	Curis Inc	CDK inhibitors containing a zinc binding moiety
WO2009036066A1 (en)	2007-09-10	2009-03-19	Curis, Inc.	Vegfr inhibitors containing a zinc binding moiety
WO2009036057A1 (en)	2007-09-10	2009-03-19	Curis, Inc.	Antiproliferative agents containing a zinc binding moiety
WO2009036020A1 (en)	2007-09-10	2009-03-19	Curis, Inc.	Mek inhibitors containing a zinc binding moiety
BRPI0816769A2 (pt)	2007-09-12	2016-11-29	Hoffmann La Roche	combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso
WO2009042646A1 (en)	2007-09-24	2009-04-02	Curis, Inc.	Anti-proliferative agents
US8129371B2 (en) *	2007-10-16	2012-03-06	Wyeth Llc	Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors
WO2009055730A1 (en)	2007-10-25	2009-04-30	Genentech, Inc.	Process for making thienopyrimidine compounds
US20090149511A1 (en)	2007-10-30	2009-06-11	Syndax Pharmaceuticals, Inc.	Administration of an Inhibitor of HDAC and an mTOR Inhibitor
WO2009086012A1 (en)	2007-12-20	2009-07-09	Curis, Inc.	Aurora inhibitors containing a zinc binding moiety
EP2311842A3 (en)	2008-06-24	2011-07-13	Takeda Pharmaceutical Company Limited	PI3K/M TOR inhibitors
WO2009155659A1 (en)	2008-06-27	2009-12-30	The University Of Queensland	Combination therapy
PT2385832E (pt)	2009-01-08	2015-11-02	Curis Inc	Inibidores de fosfoinoritide 3-quinase com uma fração de ligação ao zinco
JP5709766B2 (ja)	2009-03-12	2015-04-30	ジェネンテック，インコーポレイテッド	造血器腫瘍の治療のためのホスホイノシチド３キナーゼ阻害剤化合物と化学療法剤の併用
AU2010314287A1 (en)	2009-10-12	2012-05-03	F. Hoffmann-La Roche Ag	Combinations of a PI3K inhibitor and a MEK inhibitor
CA2795952A1 (en) *	2010-04-16	2011-10-20	Curis, Inc.	Treatment of cancers having k-ras mutations
PT3111938T (pt)	2011-04-01	2019-07-10	Curis Inc	Inibidores de fosfoinoritide 3-quinase com uma fração de ligação ao zinco
US20130102595A1 (en)	2011-04-15	2013-04-25	Curis, Inc.	Treatment of cancers having k-ras mutations

2010
- 2010-01-08 PT PT107295669T patent/PT2385832E/pt unknown
- 2010-01-08 EP EP10729566.9A patent/EP2385832B1/en active Active
- 2010-01-08 MX MX2011007326A patent/MX2011007326A/es active IP Right Grant
- 2010-01-08 SI SI201031013T patent/SI2385832T1/sl unknown
- 2010-01-08 KR KR1020147014945A patent/KR20140094590A/ko not_active Withdrawn
- 2010-01-08 HU HUE10729566A patent/HUE027615T2/en unknown
- 2010-01-08 CN CN201080010977.1A patent/CN102341108B/zh active Active
- 2010-01-08 DK DK10729566.9T patent/DK2385832T3/en active
- 2010-01-08 JP JP2011545452A patent/JP5452617B2/ja active Active
- 2010-01-08 BR BRPI1004899A patent/BRPI1004899B8/pt active IP Right Grant
- 2010-01-08 US US12/684,594 patent/US8367663B2/en active Active
- 2010-01-08 RS RS20150596A patent/RS54230B1/sr unknown
- 2010-01-08 EA EA201101053A patent/EA024252B1/ru unknown
- 2010-01-08 AU AU2010203512A patent/AU2010203512C1/en active Active
- 2010-01-08 PL PL10729566T patent/PL2385832T3/pl unknown
- 2010-01-08 SG SG2011049848A patent/SG172908A1/en unknown
- 2010-01-08 SG SG2014002737A patent/SG196815A1/en unknown
- 2010-01-08 ME MEP-2015-149A patent/ME02230B/me unknown
- 2010-01-08 HR HRP20150947TT patent/HRP20150947T1/hr unknown
- 2010-01-08 KR KR1020117018181A patent/KR101430424B1/ko active Active
- 2010-01-08 WO PCT/US2010/020495 patent/WO2010080996A1/en not_active Ceased
- 2010-01-08 ES ES10729566.9T patent/ES2550032T3/es active Active
- 2010-01-08 TW TW099100348A patent/TWI558710B/zh active
- 2010-01-08 CA CA2749228A patent/CA2749228C/en active Active
2011
- 2011-04-01 US US13/078,769 patent/US8461157B2/en active Active
- 2011-07-07 IL IL213976A patent/IL213976A/en active IP Right Grant
2013
- 2013-05-13 US US13/892,373 patent/US8906909B2/en active Active
- 2013-12-27 JP JP2013271719A patent/JP5762520B2/ja active Active
2014
- 2014-11-12 US US14/539,327 patent/US9725461B2/en active Active
2015
- 2015-03-12 IL IL237727A patent/IL237727A0/en unknown
- 2015-06-09 JP JP2015116323A patent/JP2015187145A/ja not_active Withdrawn
- 2015-09-24 SM SM201500226T patent/SMT201500226B/xx unknown
- 2015-10-13 CY CY20151100919T patent/CY1116797T1/el unknown
2017
- 2017-06-29 US US15/637,448 patent/US10336770B2/en active Active
2019
- 2019-05-29 US US16/425,316 patent/US10676482B2/en active Active
2020
- 2020-05-12 US US15/930,103 patent/US10894795B2/en active Active
- 2020-12-23 US US17/132,399 patent/US11261195B2/en active Active
2022
- 2022-01-27 US US17/585,701 patent/US11597732B2/en active Active
2023
- 2023-01-13 US US18/097,038 patent/US20230227467A1/en not_active Abandoned
2024
- 2024-08-23 US US18/813,989 patent/US20250230169A1/en active Pending

Also Published As

Publication number	Publication date
IL213976A0 (en)	2011-08-31
US20140155595A1 (en)	2014-06-05
CA2749228C (en)	2016-05-17
IL213976A (en)	2015-03-31
BRPI1004899B1 (pt)	2020-08-18
TW201030009A (en)	2010-08-16
RS54230B1 (sr)	2015-12-31
US20250230169A1 (en)	2025-07-17
US10676482B2 (en)	2020-06-09
KR101430424B1 (ko)	2014-08-14
JP5452617B2 (ja)	2014-03-26
US20150203509A1 (en)	2015-07-23
SG172908A1 (en)	2011-08-29
US9725461B2 (en)	2017-08-08
HUE027615T2 (en)	2016-10-28
IL237727A0 (en)	2015-05-31
JP2012514650A (ja)	2012-06-28
US20220402934A1 (en)	2022-12-22
ES2550032T3 (es)	2015-11-04
EA201101053A1 (ru)	2012-02-28
KR20140094590A (ko)	2014-07-30
CN102341108B (zh)	2015-05-27
JP2015187145A (ja)	2015-10-29
AU2010203512C1 (en)	2013-10-17
AU2010203512B2 (en)	2013-03-14
US8461157B2 (en)	2013-06-11
US8367663B2 (en)	2013-02-05
PT2385832E (pt)	2015-11-02
US20190352310A1 (en)	2019-11-21
CN102341108A (zh)	2012-02-01
PL2385832T3 (pl)	2016-01-29
US10336770B2 (en)	2019-07-02
US20100222343A1 (en)	2010-09-02
ME02230B (me)	2016-02-20
US11261195B2 (en)	2022-03-01
JP5762520B2 (ja)	2015-08-12
DK2385832T3 (en)	2015-09-21
EA024252B1 (ru)	2016-08-31
CA2749228A1 (en)	2010-07-15
AU2010203512A1 (en)	2011-08-11
EP2385832B1 (en)	2015-07-15
BRPI1004899B8 (pt)	2021-05-25
MX2011007326A (es)	2011-10-19
US20170362251A1 (en)	2017-12-21
US10894795B2 (en)	2021-01-19
US8906909B2 (en)	2014-12-09
HRP20150947T1 (hr)	2015-10-09
SI2385832T1 (sl)	2015-10-30
TWI558710B (zh)	2016-11-21
US20210214370A1 (en)	2021-07-15
JP2014058571A (ja)	2014-04-03
WO2010080996A1 (en)	2010-07-15
KR20110112404A (ko)	2011-10-12
HK1164113A1 (en)	2012-09-21
US20200339593A1 (en)	2020-10-29
US20120088764A1 (en)	2012-04-12
SMT201500226B (it)	2015-10-30
EP2385832A4 (en)	2012-07-25
CY1116797T1 (el)	2018-03-07
EP2385832A1 (en)	2011-11-16
US11597732B2 (en)	2023-03-07
US20230227467A1 (en)	2023-07-20
SG196815A1 (en)	2014-02-13

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-03-26	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-05-21	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2019-08-20	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2020-01-21	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2020-05-19	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-08-18	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/08/2020, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/01/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2022-08-02	B25G	Requested change of headquarter approved	Owner name: CURIS, INC. (US)

Publication	Publication Date	Title
BR112012028530A2 (pt)	2017-12-19	composto, composição farmacêutica e seu processo de preparação e método para o tratamento de uma doença ou transtorno
BR112013026341A2 (pt)	2019-09-24	composto, composição farmacêutica, e, método para tratar, prevenir e/ou atrasar o início de uma doença ou patologia
BR112014011671A2 (pt)	2017-05-30	composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto
BR112015003332A2 (pt)	2017-09-26	composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112012004333A2 (pt)	2015-09-08	composto, composição farmacêutica, e, método para o tratamento ou a prevenção de uma doença ou um distúrbio.
BR112015003398A2 (pt)	2018-04-24	composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112014004181A2 (pt)	2017-06-13	composto, composição farmacêutica, e, método de tratamento, prevenção, e / ou retardo do início de uma doença ou patologia
BR112013025340A2 (pt)	2016-12-13	composto, composição farmacêutica, método para tratar uma doença ou distúrbio relacionado com pi3k num indivíduo necessitado, método para tratar doença mediada por hdac e método para tratar tanto doenças mediadas por pi3k como por hdac
BR112015001098A2 (pt)	2017-08-08	composto, composição farmacêutica e método para o tratamento de uma condição de doença.
BRPI0813725A2 (pt)	2014-12-30	Métodos e composições para tratamento de doenças
BR112015003397A2 (pt)	2019-09-24	composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
BRPI1013984A2 (pt)	2018-06-19	composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto.
BRPI0915382A2 (pt)	2017-06-27	composto, composição farmacêutica, e, método para tratar uma doença ou um distúrbio.
BRPI0814503A2 (pt)	2017-05-16	composto, uso de um composto, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente, e para tratar uma doença, e, composição farmacêutica
BRPI1008974A2 (pt)	2017-06-06	composto, composição farmacêutica, e, método para tratar, prevenir ou melhorar uma doença mediada com gsk-3
BRPI0912111A2 (pt)	2015-10-06	composto, composição farmacêutica, método para tratar, controlar ou prevenir uma doença ou distúrbio, e, forma de dosagem unitária única
BR112014010186A2 (pt)	2017-05-02	formulação farmacêutica estável, kit, composição farmacêutica, método para preparar uma formulação farmacêutica, e, método para tratar um humano ou animal
BRPI0815387A2 (pt)	2017-05-23	composição farmacêutica, método para fazer uma composição farmacêutica e método de tratar uma condição
BRPI0822398A2 (pt)	2014-11-18	Forma sólida, mistura, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou distúrbio e um câncer
BR112013020352A2 (pt)	2017-08-08	composto, composição farmacêutica, uso de um composto e método para tratar doença ou condição mediana por rorgamat num indivíduo
BR112014010177A2 (pt)	2017-04-25	composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença
BR112012018947A8 (pt)	2017-12-19	composição farmacêutica para o tratamento e/ou prevenção de um câncer, anticorpo, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer
BRPI0905733A2 (pt)	2015-12-01	"composição, formulação farmacêutica, método para tratamento de câncer positivo para her2 e método pára a produção de uma composição farmacêutica"
BRPI0812851A2 (pt)	2014-09-30	Composto, composição farmacêutica, métodos para o tratamento de uma doença e de uma condição em um indivíduo, processo para preparar um composto, e, uso de um composto
BR112014003296A2 (pt)	2017-03-14	composto, composição farmacêutica, processo para a preparação de uma composição farmacêutica, método para o tratamento de uma doença ou distúrbio, conjunto para o tratamento de uma condição mediada pela quinase pim e utilização do composto